ClinicalTrials.gg
RecruitingNCT05870163Updated Apr 1, 2025

Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment

An observational study in Gastroesophageal Reflux Disease (GERD), sponsored by Implantica CE Reflux Ltd.. Recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by Implantica CE Reflux Ltd. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 78 studies in Gastroesophageal Reflux with a site in Italy — 12 open to participants now, 14 under way, none of them phase 3. Gastroesophageal Reflux · Italy.

Planned enrollment
4th of 30
2,500 · median 139
Started
2023
with 3 others
Observational
30 of 78
7 open now
Primary completion
2025-12
later than 4 of 13 live
Registered
62nd of 78
by date

Among the 78 studies in Gastroesophageal Reflux with a site in Italy, this one is the 4th largest by planned enrollment of the 30 observational ones that give a count, is one of 4 that started in 2023, is one of 30 observational ones, reaches primary completion later than 4 of the 13 other live ones, and was the 62nd registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

12 of the 78 studies in Gastroesophageal Reflux with a site in Italy are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Gastroesophageal Reflux with a site in Italy, or all of them as a file.
02

Study summary

This post-market registry aims to assess safety and performance of RefluxStop™ in the treatment of Gastroesophageal Reflux Disease (GERD) in standard of care procedures.

03

Conditions studied

  • Gastroesophageal Reflux Disease (GERD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

RefluxStop device and Nissen fundoplication are indicated for patients diagnosed with Gastroesophageal Reflux Disease (GERD) defined by abnormal pH testing.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide and to participate in the registry study,
  2. Patient's age ≥ 18 years or according to local legal age of adulthood if older,
  3. Documented GERD present for > 6 months,
  4. Patient has a 24-hour pH monitoring proven GERD with pH and/or impedance pH measurement, off PPI therapy for at least 7 days prior to testing. (Total distal esophageal pH must be \<4 for >4.5% of time during a 24-hour monitoring and/or total reflux episodes of acid >55 or weakly acid >26 for >5 seconds at 5 cm above LES)
  5. Suitable to undergo general anesthesia and is a suitable laparoscopic surgery candidate as determined by the investigator.

Exclusion criteria

Exclusion criteria:

  1. Presence of para-esophageal hernia or sliding hernia > 3 centimeters,
  2. Known presence of delayed gastric emptying, if no other cause for acid reflux could be diagnosed,
  3. History of bariatric surgery wherein the stomach fundus has been extirpated,
  4. Female patients who are pregnant or nursing,
  5. Known sensitivity or allergies to silicone materials,
  6. Intraoperative findings determined by the investigator that may result in unfavorable conduct of the registry study procedure (as outlined in the IFU);
  7. Patients that are unable to comply with the registry study requirements, (for example due to major psychiatric disorder or are considered otherwise unsuitable for participation in the registry study according to the investigator's judgement).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • RefluxStop patients

    Device: RefluxStop implantation

  • Nissen fundoplication patients

    Procedure: Nissen fundoplication

Interventions

  • DeviceRefluxStop implantation

    Standard surgical technique for implantation RefluxStop, as described in the Itructions for Use

  • ProcedureNissen fundoplication

    Standard of care Nissen fundoplication surgery

06

What researchers measure

Primary outcomes

  1. Primary safety endpoint

    Incidence of Serious Adverse Device Effects (SADEs), Serious Adverse Events (SAEs) and Device Deficiencies (DDs)

    Time frame: 6 months

  2. Primary performance endpoint

    Assessment of GERD symptoms, measured by GERD Health-Related Quality of Life (HRQL) score (questions 1-10). (An answer of zero means no symptoms)

    Time frame: 6 months

Secondary outcomes

  1. Secondary safety endpoint

    Incidence of Serious Adverse Device Effects (SADEs), Serious Adverse Events (SAEs) and Device Deficiencies (DDs) at 3 months and annually up to 5 years. Plus Incidence of Adverse Device Effects (ADEs) and procedure related or unknown Adverse Events (AEs) at 3 and 6 months and annually up to 5 years

    Time frame: 3 and 6 months and annually up to 5 years

  2. Secondary performance endpoints

    Assessment of GERD symptoms, assessed by GERD-HRQL score (questions 1-10)

    Time frame: 3 months and annually up to 5 years

  3. Secondary performance endpoints: RefluxStop device position

    Location and function of the device evaluated by a simplified contrast swallow x-ray with overview pictures of device

    Time frame: 6 months

  4. Secondary performance endpoints: hernia assessment

    Location of baseline hernia or any new hernia by a simplified contrast swallow x-ray picture

    Time frame: 6 months

  5. Secondary performance endpoints: pH monitoring

    Reduction or normalisation from baseline of the total acid (pH\<4) exposure time during 24-hour pH monitoring

    Time frame: 6 months

Other outcomes

  1. Exploratory endpoints: Patient Reported Outcomes - Quality of life questionnaire

    EQ-5D (Euro Quality of life-5 Dimension) questionnaire: measure of quality of life with one question for each of the five dimensions that are mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, the patients assess if they have no problem, slight, moderate, severe or extreme problems.

    Time frame: 3 and 6 months and annually up to 5 years

  2. Exploratory endpoints: Patient Reported Outcomes - Work related questionnaire

    WPAI (work related productivity gains): 5 questions to assess how health problems effect the patient work Score 0 to 10. Zero meaning health problems have no effect on work

    Time frame: 3 and 6 months and annually up to 5 years

  3. Exploratory endpoints: Health economic outcomes - Visit to General Practitioner

    Evaluation of number of visit to the General Practitioner

    Time frame: 3 and 6 months and annually up to 5 years

  4. Exploratory endpoints: Health economic outcomes - PPI treatment use

    Counting of the number of patients using PPI (Proton Pump Inhibitors)

    Time frame: 3 and 6 months and annually up to 5 years

  5. Exploratory endpoints: Health economic outcomes - Re-admission to hospital

    Counting of the number of re-admission to hospital due to complications

    Time frame: 3 and 6 months and annually up to 5 years

  6. Exploratory endpoints: Health economic outcomes - Procedure costs

    Evaluation of the costs related to the study procedure and the length of hospital stay

    Time frame: 3 and 6 months and annually up to 5 years

07

Study locations

5 of 6 sites recruiting
  • Klinikum Friedrichshafen GmbH
    Friedrichshafen, 88048, Germany
    Active, not recruiting

    Not enrolling at this site.

  • Ospedale IRCCS Saverio De Bellis
    Bari, 70013, Italy
    Recruiting
    • Leonardo Vincenti · Contact
  • Ospedale Buon Consiglio Fatebenefratelli
    Napoli, 80123, Italy
    Recruiting
    • Adolfo Renzi · Contact
  • Akershus Universitetssykehus HF
    Lørenskog, 1478, Norway
    Recruiting
    • Lars Eftang · Contact
  • Inselspital, Universitätsspital Bern
    Bern, 3010, Switzerland
    Recruiting
    • Yves Borbély, Dr. med. · Contact
  • Hirslanden Klinik
    Bern, 3013, Switzerland
    Recruiting
    • Jörg Zehetner, Pr. · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2025, 33 months after the start.

Of 117 observational studies under Gastroesophageal Reflux, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 134. This study's planned 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2023
First posted
May 23, 2023
StartActual
Feb 20, 2023
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 31, 2029
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05870163
Lead sponsor
Implantica CE Reflux Ltd.
Responsible party
Sponsor
First posted
May 23, 2023
Start date
Feb 20, 2023
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Apr 1, 2025

Study contacts

Souheila Moutiq
Contact
souheila.moutiq@implantica.com
+41 78 249 77 28
Yves Borbély, Dr. med.
principal investigator · Inselspital, Universitätsspital Bern

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion